Physician profile
Eric Jw Choe
NPI 1669576377
$6,631.15
in general payments reported to CMS, 2019-2025
27 companies · $234 in 2025
The $234 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,554 · 2020: $594 · 2021: $996 · 2022: $1,448 · 2023: $1,060 · 2024: $745 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,974 · Education: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,974.24 |
| Education | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,377.67 | 2019-2024 | Xtandi, Myrbetriq, Veozah |
| Janssen Biotech, INC. | $980.28 | 2019-2024 | Erleada, Akeega |
| Gilead Sciences, INC. | $657.96 | 2019-2023 | Vemlidy |
| Pfizer INC. | $625.85 | 2019-2024 | |
| Teleflex LLC | $493.23 | 2021-2024 | Urolift |
| Urovant Sciences INC | $479.68 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $234.24 | 2025 | |
| Acerus Pharmaceuticals Corporation | $213.56 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $194.21 | 2023-2024 | Gemtesa |
| Abbott Laboratories | $169.16 | 2019 | |
| Urogen Pharma, INC. | $165.35 | 2020-2024 | Jelmyto |
| Endo Pharmaceuticals INC. | $157.96 | 2019-2020 | |
| Dexcom, INC. | $134.07 | 2024 | Dexcom G7 Gss (161) |
| Novo Nordisk INC | $124.06 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $122.89 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $121.86 | 2023 | Evenity |
| Astrazeneca Pharmaceuticals LP | $96.45 | 2023 | Farxiga |
| Aytu Biopharma, INC. | $78.69 | 2019 | |
| Laborie Medical Technologies Corp. | $40.11 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Allergan, INC. | $36.94 | 2019 | |
| Halozyme INC | $20.36 | 2023 | |
| Tolmar, INC. | $20.30 | 2023 | |
| Janssen Pharmaceuticals, INC | $20.14 | 2019 | |
| Abbvie INC. | $17.73 | 2020 | |
| Genzyme Corporation | $17.45 | 2023 | |
| Mission Pharmacal Company | $16.11 | 2022 | |
| Immunitybio, INC. | $14.84 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Choe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.